Review of results from three randomized controlled trials (MDX010-20, KEYNOTE-002, and CheckMate 067) suggested that ipilimumab, nivolumab, and pembrolizumab, as monotherapy or combination therapy of nivolumab plus ipilimumab or ipilimumab plus gp100 vaccine, either improved or maintained the health-related quality of life (HRQOL) in advanced melanoma patients [19]. The gene discussed is PMEL; the disease is melanoma.